Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference
Rhea-AI Summary
Ceribell, a medical technology company specializing in neurological diagnostics, has announced its participation in the upcoming Bank of America Securities 2025 Health Care Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., will deliver a presentation on Wednesday, May 14, 2025, at 10:55 AM PST (1:55 PM EST).
The presentation will be accessible to interested parties through a live webcast, which will also be archived for future reference. Viewers can access the webcast through the Investor Relations section of Ceribell's website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL) focuses on transforming the diagnosis and management of serious neurological conditions through innovative medical technology solutions.
Positive
- CEO presentation at a major healthcare investment conference indicates strong institutional visibility
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CBLL gained 1.18%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.
Event: Bank of America Securities 2025 Health Care Conference
Date: Wednesday, May 14, 2025
Time: 10:55 a.m. PST / 1:55p.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
When will Ceribell (CBLL) present at the Bank of America Healthcare Conference 2025?
How can investors watch Ceribell's (CBLL) presentation at the BofA Healthcare Conference?
What is Ceribell's (CBLL) focus in the medical technology sector?
Who will represent Ceribell (CBLL) at the 2025 BofA Healthcare Conference?
Where will the Bank of America Healthcare Conference featuring Ceribell (CBLL) be held?
